Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17411143 | 0.95 | HDAC2 (0.43) | HDAC2HDAC1GPR183CYP11B2SCD5 | |
| SCHEMBL15862951 | 0.86 | LMNA (0.54) | ALKGPR119PDK2ABCB1ALDH1A1 | |
| SCHEMBL22954519 | 0.86 | HDAC2 (0.52) | HDAC2HDAC1GPR183CYP11B2SCD5 | |
| SCHEMBL24793977 | 0.84 | HDAC2 (0.49) | HDAC2HDAC1GPR183CYP11B2SCD5 | |
| SCHEMBL29709716 | 0.84 | HDAC2 (0.49) | HDAC2HDAC1GPR183CYP11B2SCD5 | |
| SCHEMBL30497506 | 0.83 | CYP3A4 (0.47) | HDAC2HDAC1ALKGPR119PDK2 | |
| SCHEMBL17411226 | 0.83 | CYP3A4 (0.47) | HDAC2HDAC1ALKGPR119PDK2 | |
| SCHEMBL17411216 | 0.83 | ALDH1A1 (0.50) | GPR183CYP11B2ALDH1A1LMNAMAPT | |
| SCHEMBL12005361 | 0.83 | GPR119 (0.49) | HDAC2HDAC1GPR183CYP11B2SCD5 | |
| SCHEMBL28795270 | 0.83 | HDAC2 (0.50) | HDAC2HDAC1GPR183CYP11B2SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3165530-B1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QILU PHARMACEUTICAL CO LTD (CN) | 2018-12-05 | — | — | EP | disclosed |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | QUILU PHARMACEUTICAL CO., LTD. (CN) | 2017-05-11 | — | — | US | disclosed |
| EP-3165530-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | Qilu Pharmaceutical Co., Ltd (CN) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016000581-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | 南京明德新药研发股份有限公司 | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129909-A1 | SPIROCYCLIC ARYL PHOSPHORUS OXIDE AND ARYL PHOSPHORUS SULFIDE | ALK, ROS1, ARSA | HDAC2 3295/4885HDAC1 2432/4885GPR183 1449/4885 |
| US-10053477-B2 | Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide | ALK, ROS1, ARSA | HDAC2 3295/4885HDAC1 2432/4885GPR183 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.